310 related articles for article (PubMed ID: 27928736)
1. Antiplatelet agents in hemodialysis.
Migliori M; Cantaluppi V; Scatena A; Panichi V
J Nephrol; 2017 Jun; 30(3):373-383. PubMed ID: 27928736
[TBL] [Abstract][Full Text] [Related]
2. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
3. Updates in antiplatelet agents used in cardiovascular diseases.
Cheng JW
J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):514-24. PubMed ID: 24213473
[TBL] [Abstract][Full Text] [Related]
4. Effects of antiplatelet therapy on platelet extracellular vesicle release and procoagulant activity in health and in cardiovascular disease.
Connor DE; Ly K; Aslam A; Boland J; Low J; Jarvis S; Muller DW; Joseph JE
Platelets; 2016 Dec; 27(8):805-811. PubMed ID: 27310292
[TBL] [Abstract][Full Text] [Related]
5. Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients.
Mackman N; Spronk HMH; Stouffer GA; Ten Cate H
Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):726-732. PubMed ID: 29449336
[No Abstract] [Full Text] [Related]
6. The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease.
Nathan AS; Sen S; Yeh RW
Expert Opin Drug Saf; 2017 May; 16(5):561-572. PubMed ID: 28387542
[TBL] [Abstract][Full Text] [Related]
7. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
Wang TH; Bhatt DL; Fox KA; Steinhubl SR; Brennan DM; Hacke W; Mak KH; Pearson TA; Boden WE; Steg PG; Flather MD; Montalescot G; Topol EJ;
Eur Heart J; 2007 Sep; 28(18):2200-7. PubMed ID: 17673448
[TBL] [Abstract][Full Text] [Related]
8. Low-dose aspirin for prevention of cardiovascular disease in patients on hemodialysis: A 5-y prospective cohort study.
Liu J; Pan Y; Chen L; Qiao QY; Wang J; Pan LH; Gu YH; Gu HF; Fu SK; Jin HM
Hemodial Int; 2016 Oct; 20(4):548-557. PubMed ID: 26932276
[TBL] [Abstract][Full Text] [Related]
9. Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar.
Cheng JW
Vasc Health Risk Manag; 2016; 12():263-8. PubMed ID: 27366081
[TBL] [Abstract][Full Text] [Related]
10. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Reaume KT; Regal RE; Dorsch MP
Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
[TBL] [Abstract][Full Text] [Related]
11. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
; Anand S; Yusuf S; Xie C; Pogue J; Eikelboom J; Budaj A; Sussex B; Liu L; Guzman R; Cina C; Crowell R; Keltai M; Gosselin G
N Engl J Med; 2007 Jul; 357(3):217-27. PubMed ID: 17634457
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
Jackson LR; Ju C; Zettler M; Messenger JC; Cohen DJ; Stone GW; Baker BA; Effron M; Peterson ED; Wang TY
JACC Cardiovasc Interv; 2015 Dec; 8(14):1880-9. PubMed ID: 26718518
[TBL] [Abstract][Full Text] [Related]
13. The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting.
Breet NJ; de Jong C; Bos WJ; van Werkum JW; Bouman HJ; Kelder JC; Bergmeijer TO; Zijlstra F; Hackeng CM; Ten Berg JM
Thromb Haemost; 2014 Dec; 112(6):1174-81. PubMed ID: 25231776
[TBL] [Abstract][Full Text] [Related]
14. Aspirin resistance in patients with chronic renal failure.
Tanrikulu AM; Ozben B; Koc M; Papila-Topal N; Ozben T; Caymaz O
J Nephrol; 2011; 24(5):636-46. PubMed ID: 21279952
[TBL] [Abstract][Full Text] [Related]
15. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
Lamberts M; Gislason GH; Olesen JB; Kristensen SL; Schjerning Olsen AM; Mikkelsen A; Christensen CB; Lip GY; Køber L; Torp-Pedersen C; Hansen ML
J Am Coll Cardiol; 2013 Sep; 62(11):981-9. PubMed ID: 23747760
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet drugs: which targets for which treatments?
Gachet C
J Thromb Haemost; 2015 Jun; 13 Suppl 1():S313-22. PubMed ID: 26149041
[TBL] [Abstract][Full Text] [Related]
17. Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices.
Faxon DP
Rev Cardiovasc Med; 2005; 6 Suppl 4():S3-14. PubMed ID: 17710074
[TBL] [Abstract][Full Text] [Related]
18. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
[TBL] [Abstract][Full Text] [Related]
19. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
[TBL] [Abstract][Full Text] [Related]
20. Is aspirin still the drug of choice for management of patients with peripheral arterial disease?
Poredos P; Jezovnik MK
Vasa; 2013 Mar; 42(2):88-95. PubMed ID: 23485835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
